A Phase III Study of JSKN016 Versus Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

​ Conditions: Triple Negative Breast Cancer

Interventions: Drug: JSKN016 Injection; Drug: Eribulin Mcsilate Injection; Drug: Vinorelbine Tartrate Injection; Drug: Capecitabine Tablets; Drug: Gemcitabine Hydrochloride for Injection; Drug: Sacituzumab Govitecan for Injection

Sponsors: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting Conditions: Triple Negative Breast Cancer
Interventions: Drug: JSKN016 Injection; Drug: Eribulin Mcsilate Injection; Drug: Vinorelbine Tartrate Injection; Drug: Capecitabine Tablets; Drug: Gemcitabine Hydrochloride for Injection; Drug: Sacituzumab Govitecan for Injection
Sponsors: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Recruiting